NASDAQ:APRE | Free Cash Flow | Aprea Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2017-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$2.76M
2025-12-31-$2.96M
2025-03-31-$3.63M
2024-12-31-$3.51M$0.00-$3.51M
2024-03-31-$3.94M$7,978.00-$3.94M
2023-12-31-$3.74M$7,150.00-$3.75M
2023-03-31-$2.98M
2022-12-31-$4.02M
2022-03-31-$5.5M
2021-12-31-$10.18M
2021-03-31-$11.52M
2020-12-31-$13.2M$16,290.00-$13.22M
2020-03-31-$7.54M$12,165.00-$7.55M
2019-12-31-$14.74M$14,466.00-$14.76M
2019-03-31-$4.2M
2018-12-31-$3.85M-$804.00-$3.85M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$12.89M
2024-12-31-$13.56M$15,478.00-$13.57M
2023-12-31-$12.18M$93,093.00-$12.27M
2022-12-31-$25.01M
2021-12-31-$37.69M
2020-12-31-$41.8M$25,709.00-$41.83M
2019-12-31-$26.71M$30,901.00-$26.74M
2018-12-31-$15.25M$3,702.00-$15.25M
2017-12-31-$14M